220 related articles for article (PubMed ID: 11822766)
1. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
[TBL] [Abstract][Full Text] [Related]
2. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
4. The effects of food and divided dosing on the bioavailability of oral vinorelbine.
Rowinsky EK; Lucas VS; Hsieh AL; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Donehower RC
Cancer Chemother Pharmacol; 1996; 39(1-2):9-16. PubMed ID: 8995494
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
[TBL] [Abstract][Full Text] [Related]
6. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
7. The absolute bioavailability of oral vinorelbine in patients with solid tumors.
Lush RM; McCune JS; Tetteh L; Thompson JA; Mahany JJ; Garland L; Suttle AB; Sullivan DM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):578-84. PubMed ID: 16001165
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials.
Delord JP; Bennouna J; Mourey L; Bougaret J; Brandely-Talbot M; Ferré P
Clin Pharmacokinet; 2012 Jun; 51(6):357-64. PubMed ID: 22471295
[TBL] [Abstract][Full Text] [Related]
10. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
11. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of vinorelbine.
Levêque D; Jehl F
Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
14. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
[TBL] [Abstract][Full Text] [Related]
15. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
16. The effects of food on the pharmacokinetic profile of oral vinorelbine.
Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
[TBL] [Abstract][Full Text] [Related]
17. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics.
Puozzo C; Gridelli C
Clin Lung Cancer; 2004 Jan; 5(4):237-42. PubMed ID: 14967076
[TBL] [Abstract][Full Text] [Related]
18. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.
Jassem J; Ramlau R; Karnicka-Młodkowska H; Krawczyk K; Krzakowski M; Zatloukal P; Lemarié E; Hartmann W; Novakova L; O'Brien M; Depierr A
Ann Oncol; 2001 Oct; 12(10):1375-81. PubMed ID: 11762807
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
[TBL] [Abstract][Full Text] [Related]
20. Oral vinorelbine: feasibility and safety profile.
Depierre A; Freyer G; Jassem J; Orfeuvre H; Ramlau R; Lemarie E; Koralewski P; Mauriac L; Breton JL; Delozier T; Trillet-Lenoir V
Ann Oncol; 2001 Dec; 12(12):1677-81. PubMed ID: 11843244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
